Natural history of adrenal steroidogenesis in autoimmune Addison\u27s disease following diagnosis and treatment by Napier C et al.
Ac
ce
pte
d M
an
us
cri
pt
 
© Endocrine Society 2020. jc.2019-40672 See endocrine.org/publications for Accepted 
Manuscript disclaimer and additional information. 
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits 
unrestricted reuse, distribution, and reproduction in any medium, provided the original 
work is properly cited. 
Natural history of adrenal steroidogenesis in autoimmune Addison’s disease following diagnosis 
and treatment 
 
 
 
Catherine Napier,1 Kathleen Allinson,1 Earn H Gan,1 Anna L Mitchell,1 Lorna C Gilligan,2 Angela E 
Taylor,2 Wiebke Arlt,2 Simon HS Pearce1 
 
 
 
 
 
1 Institute of Genetic Medicine, International Centre for Life, Newcastle University, Newcastle upon 
Tyne, NE1 3BZ; and Newcastle upon Tyne Hospitals NHS Trust, Royal Victoria Infirmary, Queen 
Victoria Road, NE1 4LP, UK. 
 
2 Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, B15 
2TT, UK; and NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS 
Foundation Trust and University of Birmingham, Birmingham, B15 3GW, UK. 
 
 
 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/clinem
/dgaa187/5821191 by U
niversity of N
ew
castle,  sim
on.pearce@
ncl.ac.uk on 04 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
 
 2 
Address for Correspondence: 
 
Dr. Catherine Napier, 
Endocrine Unit, 
Leazes Wing, 
Royal Victoria Infirmary, 
Newcastle upon Tyne Hospitals,  
Queen Victoria Road,  
NE1 4LP, UK  
 
Tel: (+44) 191 2820590 
Email: C.Napier@nhs.net 
 
 
Disclosures 
SHSP has consulted for Apitope and received speaker fees from Quidel, Berlin Chemie and Sanofi. All 
other authors have no conflict of interest to declare. 
 
 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/clinem
/dgaa187/5821191 by U
niversity of N
ew
castle,  sim
on.pearce@
ncl.ac.uk on 04 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
 
 3 
ABSTRACT 
Context: The natural history of adrenal function in autoimmune Addison’s disease once diagnosed 
and treated has not been systematically studied, but several case reports of recovery from 
established adrenal failure suggest it may not be uniform. 
Objective: To ascertain steroidogenic function in autoimmune Addison’s disease immediately 
following diagnosis and during prolonged treatment. 
Design: We studied peak serum cortisol in response to ACTH1-24 in 20 newly diagnosed autoimmune 
Addison’s disease patients at first presentation and then again within a month. We also studied 37 
patients with established Addison’s disease (for between 7 months and 44 years) in a medication-
free state, measuring peak serum cortisol responses to ACTH1-24 and the urine LC-MS steroid 
metabolome. 
Results: Adrenal steroidogenesis declined rapidly after steroid replacement treatment for newly 
diagnosed Addison’s disease was started, with a peak serum cortisol falling from 138 ± 19nmol/l 
(SEM) at presentation to 63 ± 13nmol/L over 4 weeks (P<0.003). 
Six of 37 participants (16%) with established Addison’s disease had detectable serum cortisol and 
urine glucocorticoid and mineralocorticoid metabolites during repeat testing, indicating variable 
degrees of residual adrenal function. 
Conclusion: Autoimmune Addison’s disease is a heterogeneous condition, showing a rapid decline in 
adrenal steroidogenesis during the first few weeks following diagnosis, but low-level residual 
function in a minority of patients, which appears to persist for many years. 
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INTRODUCTION 
 
Autoimmune Addison’s disease (AAD) is a rare endocrinopathy characterised by immune-mediated 
destruction of the adrenal cortex.1 Without treatment, it is invariably fatal, but once diagnosed 
health can be maintained with daily glucocorticoid and mineralocorticoid replacement tablets.2-4 
Symptoms of AAD frequently start months or years before the condition is diagnosed,5,6 and current 
thinking is that it progresses to a ‘point of no return’ where complete adrenocortical steroidogenic 
failure is inevitable and universal.7 Despite this assumption, several instances showing apparent 
spontaneous remission of well-characterised AAD have been reported in patients several years after 
an initial firm diagnosis.8-10 In addition, one study reported reduction in adrenal autoantibody titre 
and improved adrenal function in a pre-symptomatic individual following high-dose prednisolone 
therapy for co-existing Graves’ orbitopathy.11 These studies start to suggest that adrenocortical 
steroidogenesis may exhibit some plasticity both at first presentation of Addison’s disease, and 
perhaps persisting post-diagnosis and treatment of AAD. With this in mind, we previously studied 13 
patients with established AAD and found that two (15%) had detectable steroidogenesis 4 and 8 
years post-diagnosis, which was amenable to improvement with high-dose ACTH therapy.12 One of 
these individuals remains healthy without steroid medication more than 7 years later, although 
ACTH remains elevated and adrenal autoantibodies remain detectable. 
 
Whether there is residual adrenocortical steroidogenesis in some AAD patients, therefore, has 
become an important issue, because it likely indicates preservation of adrenal capsular stem cells,13-
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15 which are able to continuously repopulate the adrenal cortex despite autoimmune attack. This 
provides a potential therapeutic window, whereby persisting adrenal progenitor or stem cells may 
be harnessed to regenerate adrenal function. However, studies looking at residual steroidogenesis in 
AAD patients have come to differing conclusions. Firstly, a pioneering study from Utrecht studied 27 
AAD patients using a conventional cortisol immunoassay and found detectable ACTH1-24-stimulated 
serum cortisol in 10 patients, but concluded that there was no useful recovery of adrenal function in 
any subject.16 In contrast, a smaller but more recent study found detectable serum 11-deoxycortisol 
in 10 of 20 AAD patients using a more sensitive LC–MS/MS-based steroid assay,17 suggesting a 
prevalence of residual adrenal function of around 50%. Both studies must be interpreted with the 
proviso that participants took dexamethasone16 or hydrocortisone,17 respectively, prior to steroid 
measurements, which may have either suppressed ACTH, leading to an underestimation of 
steroidogenic capacity or cross-reacted with the cortisol assays in the case of hyd ocortisone. In this 
current study, we present data concerning the very early natural history of AAD during the first few 
weeks of conventional treatment and revisit the prevalence of residual adrenal steroidogenesis in a 
larger cohort of established AAD patients. We measured ACTH1-24-stimulated serum cortisol in all 
patients and carried out comprehensive urine steroid metabolite profiling by tandem mass 
spectrometry (LC-MS/MS). 
 
PATIENTS & METHODS 
Newly presenting autoimmune Addison’s disease 
In 20 patients, serum cortisol data were captured at first presentation with newly diagnosed 
Addison’s disease, followed by a plasma ACTH measurement and a formal short synacthen (ACTH1-24 
stimulation) test within 4 weeks of the commencement of oral glucocorticoid replacement. These 
participants were recruited for enrolment into two different studies (NCT00753597, 
ISRCTN20220821), which attempted to improve adrenal function early on in the natural history of 
the condition.18,19 In both studies, participants were diagnosed with Addison’s disease in local NHS 
hospitals or at our tertiary centre and started on oral hydrocortisone replacement therapy. Serum 
cortisol measurements were captured from the day of their presentation and compared with the 
peak serum cortisol following synacthen stimulation 14-28 days later when they were assessed 
during a 36-hr medication-free baseline visit for the intervention study.18,19 All participants had 
plasma ACTH concentrations above the reference range before testing and all but one patient had 
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positive serum steroid 21-hydroxylase antibodies, and this patient went on to develop Graves’ 
disease indicating a likely autoimmune basis for her adrenal failure too.  
 
Established Addison’s disease 
Thirty-seven patients with established autoimmune Addison’s disease (AAD; diagnosis 
established more than 6 months prior to study participation) were recruited from the 
endocrine clinic at our centre (Newcastle upon Tyne Hospitals NHS Trust). A diagnosis of 
AAD was confirmed by the subjects having either a low basal cortisol level with a high ACTH 
level or a subnormal response to the short synacthen test (250 µg parenteral synthetic 
ACTH1–24). Patients with primary adrenal failure due to adrenal gland infiltration or infection, 
with secondary adrenal failure, or with autoimmune polyglandular syndrome type 1 were 
excluded.20 Following written, informed consent, they omitted their regular glucocorticoid 
and mineralocorticoid medication for a 24-h period, leading to a 36-40h medication-free 
window. One participant (patient B, see below) was previously tested during 2012 (reported 
as patient 06 in citation 12). Detailed safety information was given to the participants to 
postpone their participation if they had intercurrent illness, along with direct access to a 
member of the medical team throughout the steroid-free interval. At 18:00h on the steroid-
free day, participants started an overnight (14h) urine collection for LC-MS/MS analysis of 
the steroid metabolome. The following morning, between 08:00h and 09:00h, the urine 
collection was stopped, baseline blood was taken for plasma ACTH and serum steroid 
hormone measurements, and a short synacthen test using 250µg of IM ACTH1-24 
(tetracosactide) was performed, with repeat cortisol measurements at 30 and 60 minutes. 
Following the synacthen test participants were restarted on their usual medications. All 
studies were performed following National Research Ethics Service approval with IDs 
08/H0903/32, 12/NE/0339 and 15/NE/0312. 
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Steroid measurements 
Serum cortisol was measured by competitive chemiluminescent assay (Roche I), lower limit of 
detection (LLD) 20nmol/L. A healthy peak cortisol response to ACTH1-24 on this assay is a serum 
cortisol ≥550nmol/l. Plasma ACTH was measured on a solid-phase, chemiluminescent assay, 
LLD=5ng/l, reference range 10-47ng/l. Urine steroids were hydrolysed and extracted by solid phase 
extraction as described previously21 and analysed by LC-MS/MS in the Institute of Metabolism and 
Systems Research (IMSR) at the University of Birmingham, UK.22 To assess assay precision, pooled 
urine samples from 6 healthy males was extracted 4 times with the study samples, for all steroids a 
relative standard deviation of less than 10% was observed (0.9-6.6%). Accuracy was assessed at 3 
concentrations, 20, 400 and 1000ng/mL and ranged from -19.6 to 21.4% (excluding 5PD, PD and THB 
as <LLOQ), -18.9 to -1.2% and -2.4 to 14.3% at low, medium and high concentrations respectively.  
 
Statistical analysis 
Comparison of parametric continuous data (age, steroid doses) was performed using unpaired 
students t-test. Categorical data were analysed by Fisher’s exact test. Non-parametric continuous 
data (duration of disease, serum ACTH, cortisol measurements) were analysed by Mann Whitney U 
test. Correlation between serum cortisol and urinary steroid metabolites was performed using a 
Spearman rank test. All analysis was performed using Prism v.8.2.0 software. 
 
 
RESULTS 
Newly presenting Addison’s disease 
Twenty newly presenting AAD patients (age range 17–64 yrs, 13F) were studied on the day of first 
presentation with adrenal insufficiency, either with random or ACTH1-24–stimulated serum cortisol 
measurements. Plasma ACTH was increased in all patients at presentation (median=1050ng/L, range 
68–2630ng/L, reference range 10–47ng/L). They were subsequently treated with hydrocortisone, 
recruited for the therapeutic clinical trials and ACTH1-24–stimulated serum cortisol measurements 
were repeated 14–28 days later (median 26 days), prior to any other intervention. In 19 out of the 
20 cases stimulated serum cortisol dropped substantially over the first few weeks of hydrocortisone 
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 8 
treatment, from a median at presentation of 125nmol/L (range <23–257) to 39.5nmol/L (range <23–
265), (P<0.007; Mann Whitney U test) (Figure 1).  
 
Established Addison’s disease 
Thirty-seven patients (age range 17-75 yrs, 26 F) with established Addison’s disease from between 7 
months and 44 years duration were studied (Table 1). Thirty-six patients were confirmed to have 
primary adrenal insufficiency by an elevated plasma ACTH at baseline following steroid withdrawal 
(median=789ng/l, range 62– >1250ng/l, reference range 10–47ng/l). One subject had plasma ACTH 
in the reference range (19ng/l) in the baseline sample; a woman with a personal history of 
autoimmune thyroid disease and a sibling with autoimmune Addison’s disease and pernicious 
anaemia, who was taking multiple non-endocrine medications. There were no adverse events 
reported during steroid withdrawal. Six participants (16%) had a peak serum cortisol clearly above 
the 20nmol/l threshold for detection, whereas the remaining 31 patients showed serum cortisol less 
than 30nmol/l throughout (Figure 2). There were no obvious clinical differences between the 6 
participants with higher serum cortisol and the others (supplemental table).23 As expected for 
individuals with high circulating ACTH concentrations at baseline, there was minimal augmentation 
of serum cortisol following synacthen stimulation. LC-MS analysis of the steroid metabolome in the 
overnight urine collection from these 37 participants showed that those with detectable serum 
cortisol also had secretion of several other glucocorticoid and mineralocorticoids (Figure 2B). 
 
Interestingly, patient B (Table 1, Figure 2) previously took part in a study looking to regenerate 
adrenal function (participant 06 from Gan et al.).12 Before intervention in 2012, her peak serum 
cortisol was 184nmol/L, and when measured in 2016 for this study it was 252nmol/L suggesting that 
her residual adrenal function was static and durable between the 4 and 8 years post-diagnosis 
interval that we have been able to observe. 
 
All patients with serum cortisol >30nmol/l had detectable urine glucocorticoid and mineralocorticoid 
precursors (Figure 2). Table 2 shows the correlation of each urine steroid measured with the peak 
serum cortisol concentration during synacthen testing. Urine glucocorticoid precursor metabolites 
were most highly correlated with serum cortisol concentrations, with urine mineralocorticoids 
including dehydrocorticosterone and corticosterone metabolites being less tightly associated, and 
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 9 
adrenal androgens showing the least association. Correlation analysis between the selected urine 
metabolites and peak serum cortisol is shown in Figure 3. As expected, several urinary glucocorticoid 
precursors and metabolites and mineralocorticoids were associated with peak serum cortisol, with 
tetrahydro-11-deoxycortisol (THS) as the most significantly correlated (Table 2, Figure 3). 
Interestingly, one female participant who had negligible concentrations of serum cortisol post-
ACTH1-24 stimulation (peak 22nmol/L) had comparable levels of urine glucocorticoid precursors to 
several individuals with easily detectable serum cortisol, suggesting that urine steroid analysis may 
represent a more sensitive indicator of residual steroidogenesis (shown as an open circle on figure 
2B). This 33-year-old woman was sampled 7 months after diagnosis with AAD; her initial 
presentation being with sepsis and an adrenal crisis. She reported symptoms of fatigue and 
increasing back pain and had lost 12Kg in weight over the 4 years prior to presentation.   
 
 
DISCUSSION 
Autoimmune Addison’s disease (AAD) has a long latency before presentation in most patients5-7 and 
understanding the natural history once steroid replacement treatment has started is an important 
goal if we are to intervene to improve adrenal function in this chronic condition. The initial part of 
this study documents for the first time that serum cortisol concentrations drop rapidly within 4 
weeks following diagnosis and conventional treatment of AAD. The most plausible explanation for 
this is that the ACTH drive which maximally stimulates the adrenal cortex before diagnosis is reduced 
by the institution of regular daily glucocorticoid medication under physiological feedback. Thus prior 
to diagnosis, patients with AAD have constantly high circulating ACTH concentrations, and these 
serve to stimulate proliferation and repopulation of adrenocortical cells that are being destroyed by 
immune-mediated attack. Hyperplastic adrenocortical cells were noted many years ago in the 
adrenals from deceased AAD patients.24,25 However, once glucocorticoid replacement therapy is 
started the plasma ACTH drops to low or undetectable levels after the morning dose of 
hydrocortisone is taken each day, reducing the tropic drive to steroidogenesis and regeneration. This 
change in ACTH concentration also correlates with the improvement in pigmentation observed in 
most AAD patients following successful treatment. An alternative explanation is that patients’ 
adrenal steroidogenic function is on a steep downward trajectory at the time they are diagnosed and 
that it is declining irrespective of the steroid replacement treatment and changes to ACTH levels. 
Either way, this phenomenon seems like the opposite of the honeymoon period in type 1 diabetes,26 
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where there is frequently a transient improvement in islet cell function and insulin secretion in the 
months following initial insulin therapy. 
 
The second component of our study sought to characterise adrenal function in patients with 
established autoimmune adrenal failure treated for more than six months. The design was distinct 
from previous studies in that the oral glucocorticoid was withdrawn for 36-40 hrs prior to gold-
standard testing with synacthen stimulation, and for 24 hrs prior to the start of collection of urine 
for steroid metabolomic analysis. This study showed that 6 of 37 (16%) AAD patients had some 
evidence of residual adrenal function with detectable serum cortisol and urine glucocorticoid and 
mineralocorticoid metabolites. In addition, at least one other participant had clearly detectable 
urine steroid metabolites in the absence of a significant serum cortisol response. In common with 
the study of Vulto et al.,17 we found that the cortisol precursor, 11-deoxycortisol, appeared to be a 
sensitive marker of residual adrenal function; our study measuring urine tetrahydro-11-deoxycortisol 
and theirs using serum 11-deoxycortisol to reach the same conclusion. In addition, our study found 
multiple other glucocorticoid metabolites that were strongly associated with residual adrenal 
function and serum cortisol concentrations, proving that in these stringent, steroid medication-free 
conditions detectable serum and urine steroid metabolites represent the authentic output of low-
level residual adrenocortical function in these patients, rather than a hang-over of prior oral 
medications. In addition to glucocorticoid production, we also found significant mineralocorticoid 
secretion, which correlated more loosely with serum and urine glucocorticoid levels. In contrast, 
adrenal androgen production was unhelpful and poorly correlated with either serum glucocorticoid 
or mineralocorticoid concentrations. This is consistent with our previous observations in a small 
number of AAD individuals who improved their adrenal steroidogenesis following intervention, in 
whom no change in adrenal androgens was found despite improvements in serum cortisol and 
aldosterone concentrations.12,18 However, there was no standardisation for menopausal status or 
estrogen use in this study, introducing some heterogeneity from gonadal steroid production in this 
analysis.  
 
Our results indicate that AAD is not a homogeneous condition and that a sizeable minority of 
patients with AAD may have low-level residual adrenal function. Whether these patients represent a 
distinct cohort either in terms of their aetiopathogenesis, requirement for steroid replacements or 
resilience to adrenal crisis and other complications remains unknown. However, it seems likely that 
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there is no relationship between time since diagnosis and the presence of residual adrenal function, 
with several individuals identified with residual function by this study having had AAD treated for 
more than 10 years. Furthermore, we have been able to study one individual over 4 years and 
demonstrate that the residual adrenal function was indeed persistent. This would fit with the idea 
that the adrenocortical stem or progenitor cells remain intact and are spared the autoimmune 
attack in these individuals.12-15 In contrast to the lack of ‘honeymoon period’ in AAD, it therefore 
seems that a proportion of patients do have a durable low-level adrenal steroidogenesis, which may 
be considered parallel to persistent C-peptide positivity indicating low-level insulin secretion in 
patients with type 1 diabetes. It is clear that future studies that try to augment steroidogenesis in 
AAD patients should focus primarily on those with detectable residual adrenal function. 
 
The strength of this study lies in the design of testing participants in a medication-free state, which 
has not been done previously, and in measuring both stimulated serum cortisol concentrations and 
the urine steroid metabolome. The weaknesses are that all but one patient were studied at just a 
single time-point, and that although the largest cohort studied in this way to date, it still remains a 
relatively small cohort of AAD patients. 
 
In conclusion, our study illuminates several novel aspects of the natural history of AAD. Firstly that 
patients with newly diagnosed AAD have a rapid decline in steroidogenic capacity once replacement 
glucocorticoid medication is commenced, presumably owing to reduced adrenal ACTH exposure. We 
also show that a sizeable minority of AAD patients have durable low-level residual adrenal function 
even many years from their original diagnosis and institution of replacement therapy. This may be 
sensitively detected by serum 11-deoxycortisol or its major urinary metabolite tetrahydro-11-
deoxycortisol. These observations should help plan future intervention studies that could target 
specifically patients with residual adrenal function to ameliorate this chronic condition. 
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Table 1: Demographics and treatment of established Addison’s disease participants at study entry 
Age, sex and duration of diagnosis (in years) are included for all participants. All participants were taking 
hydrocortisone or prednisolone as glucocorticoid replacement, with 34/37 taking this in split doses across the 
day. All patients were taking fludrocortisone as mineralocorticoid replacement (once daily; range 50-900 
micrograms daily). 19/37 had 1 or more additional autoimmune disease. The six participants with a serum 
cortisol clearly above the 20nmol/l threshold for detection are labelled A-F.  
 
Patien
t ID 
Ag
e 
Se
x 
Duration 
of 
diagnosi
s (years) 
 
Plasm
a 
ACTH 
(ng/l) 
Steroid replacement 
 
Concurrent 
autoimmun
e conditions Glucocorticoi
d 
(mg) 
Mineralocorticoi
d 
(mcg) 
1
A
 24 F 3 126 HC 10+5 50 HT 
2
B
 41 F 9 651 Pred 2.5+1 100  
3
C
 59 M 11 62 HC 20+5 150  
4
D
 67 F 31 1107 HC 10+5+5 100  
5
E
 61 M 41 188 HC 15+10 100  
6
F
 52 F 10 957 HC 7.5+5 100 HT 
7 51 F 8 429 HC 10+5 100 GD 
8 34 F 3 769 Pred 3 150  
9 64 F 5 809 HC 10+5 100  
10 43 F 33 698 HC 10+10 200  
11 58 F 25 >1250 HC 10+10 50 T1DM, HT, POF 
12 58 F 13 >1250 HC 10+5+5 50 HT, PA 
13 72 M 6 591 HC 10+5+5 100  
14 75 F 10 19 Pred 3.5+2.5 150 HT 
15 48 F 13 
210 
HC 10+5 50 HT, POF, 
vitiligo 
16 57 F 17 1166 HC 10+5+2.5 100 T1DM, PA 
17 27 F 6 532 Pred 5+1 900 T1DM 
18 37 M 17 470 HC 10+10+5 100 T1DM, HT 
19 63 F 23 238 HC 10+10 150 GD 
20 68 F 44 1074 HC 10+5+5 100 HT 
21 55 F 28 983 HC 10+5 100  
22 71 F 18 >1250 HC 10+5+5 150 HT 
23 17 M 8 >1250 HC 10+5+2.5 150  
24 25 F 7 >1250 HC 10+5+5 100  
25 32 M 7 >1250 HC 10+10 100 T1DM 
26 17 M 4 >1250 Pred 5 300 T1DM, HT 
27 33 F <1 >1250 HC 15+10 100  
28 27 M 7 >1250 HC 15+10 100  
29 19 M 5 >1250 HC 10+7.5+2.5 100  
30 67 F 1 693 HC 10+5+5 100  
31 74 F 47 104 HC 10+10 50  
32 67 M 22 >1250 HC 10+5+5 150 Vitiligo 
33 24 M 8 >1250 HC 10+5+5 200  
34 69 F 41 296 HC 10+5 100  
35 60 F 19 219 HC 10+5 100 T1DM, GD, PA 
36 60 F 23 367 HC 10 100 T1DM, GD, PA 
37 46 F 19 149 HC 10+5+5 200 T1DM, HT 
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/clinem
/dgaa187/5821191 by U
niversity of N
ew
castle,  sim
on.pearce@
ncl.ac.uk on 04 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
 
 17 
HC=hydrocortisone, Pred=prednisolone 
HT=hypothyroidism, T1DM=type 1 diabetes, GD=Graves’ disease, POF=premature ovarian failure, 
PA=pernicious anaemia  
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Table 2: Spearman’s  correlation of peak post-ACTH1-24 serum cortisol vs urine steroid 
metabolome 
 
Precursor/Metabolite Spearman’s  p value 
Peak serum F = cortisol 1 (referent) 
PD = pregnanediol 0.423 0.011 
17HP = 17-hydroxyprogesterone 0.144 0.475 
PT = pregnanetriol 0.339 0.046 
PTONE = pregnanetriolone 0.644 0.037 
THS = tetrahydro-11-deoxycortisol 0.833 4.272e-007 
F = cortisol 0.825 0.001 
18OHF = 18-hydroxycortisol 0.963 0.002 
5aTHF = 5a-tetrahydrocortisol 0.682 4.727e-006 
THF = tetrahydrocortisol 0.658 1.730e-005 
a-cortol 0.456 0.015 
b-cortol 0.449 0.005 
11bOHEt = 11b-hydroxyetiocholanolone 0.426 0.011 
E = cortisone 0.934 8.209e-007 
THE = tetrahydrocortisone 0.687 2.688e-006 
a-cortolone 0.659 9.261e-006 
b-cortolone 0.538 0.001 
THAs = tetrahydro-11-dehydrocorticosterone 0.858 0.001 
5aTHB 5a-tetrahydrocorticosterone 0.787 0.016 
THB = tetrahydrocorticosterone 0.546 0.002 
THAldo = tetrahydroaldosterone 0.496 0.077 
Andros = androsterone 0.224 0.203 
Etio = etiocholanolone 0.375 0.024 
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Figure legends. 
 
Figure 1. Newly diagnosed Addison’s disease. Peak serum cortisol at presentation with autoimmune 
Addison’s disease and at one-month post diagnosis. Serum cortisol concentration measured at first 
presentation of Addison’s disease is shown in the left-hand column linked to the cortisol 
concentration taken a median of 26 days later in the same individual in the right-hand column. A 
normal peak cortisol response on this assay is ≥550nmol/L. The presentation serum cortisol fell from 
a median of 125nmol/L (range <23–257) to 39.5nmol/L (range <23–265), (P<0.007; Mann Whitney U 
test). To convert serum cortisol concentrations from nmol/L to ug/dL divide by 27.6. 
 
Figure 2. Established Addison’s disease. Peak serum cortisol following ACTH1-24 and corresponding 
urine glucocorticoid and mineralocorticoid metabolites. Serum cortisol responses at 30 and 60min 
post- ACTH1-24 are shown in Panel A. Six participants had serum cortisol concentrations ≥30nmol/L 
and these are labeled as patients A–F (highest to lowest cortisol) in subsequent figures. All the 
remaining 31 patients are overlaid with concentrations at, or close to, the limit of detection (20-
30nmol/L). Urine glucocorticoid and mineralocorticoid metabolites that were most correlated with 
serum cortisol (table 2) are shown in Panel B, with patients A–F highlighted in red. One participant 
(subject 27, table 1) who had a peak serum cortisol of 22nmol/L nevertheless had consistently 
detectable urine glucocorticoid and mineralocorticoid metabolites and is shown as an open circle. 
Abbreviated metabolite names are shown in full in table 2. Individual participant correlations 
between peak serum cortisol and the most associated urine glucocorticoid and mineralocorticoid 
metabolites are shown in figure 3. 
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Figure 3. Comparison of peak serum cortisol and urine steroid metabolome. Peak serum cortisol (F) 
plotted against selected urinary corticosteroid metabolites (Panel A). Correlation heatmap 
(Spearman ρ) for serum cortisol and selected urine glucocorticoids and mineralocorticoids (Panel B). 
The Spearman’s rank correlation coefficient (ρ) between each pair of urine or serum glucocorticoid 
or mineralcorticoids is shown in the intersecting square, along with a shaded background indicating 
the strength of the correlation. Urine glucocorticoid metabolites were more closely associated with 
peak serum cortisol than mineralocorticoid metabolites. Abbreviated metabolite names are shown 
in full in table 2.
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Figure 1. Peak serum cortisol at presentation with autoimmune Addison’s disease and at one month 1 
post diagnosis 2 
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Figure 2. Peak serum cortisol following ACTH1-24 and corresponding urine glucocorticoid and 19 
mineralocorticoid metabolites in patients with established Addison’s disease. 20 
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 33 
Figure 3. Analysis of steroid metabolome. Panel A: Comparison of peak serum cortisol (F) to selected 34 
urinary corticosteroid metabolites. Panel B: Correlation heatmap (Spearman ρ) for serum cortisol 35 
and selected urine glucocorticoids and mineralocorticoids 36 
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Panel B: 41 
 42 
 43 
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